The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.

Also called NCT06058585

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06058585
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Australia, India, New Zealand, Spain, Sri Lanka (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06058585. Randomized; quadruple masking; primary purpose treatment. Start 2024-09-04 (actual); primary completion 2029-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
Acronym
CAPTIVATE
Condition
Chronic Kidney Diseases
Intervention (Drug)
Finerenone
Intervention (Drug)
Placebo Finerenone
Intervention (Drug)
Semaglutide
Intervention (Drug)
Placebo semaglutide
Lead sponsor
The George Institute (class: other)

Record details

Record id
cardio:ct-nct06058585
Content hash
f4d9afeedfce79e35b5044cc765c26c82950a1aa75a652d370074ed5310d629e